As International Vice President of Cancer Research at Glaxo Wellcome (now GSK) and Associate Director of Experimental Therapy and Principal Scientist at Burroughs Wellcome, President of Spector Consulting Services, and Chief Scientific Officier for Adherex Technologies, Dr. Spector’s drug discovery experience spanned a broad range of therapeutic areas.
- CANCER THERAPY
- ANTIVIRAL AGENTS
- OTHER ANTIINFECTIVE AGENTS
- PHARMACODYNAMIC AGENTS
Dr. Spector’s personal research mainly involved drug interactions with chemotherapeutically important enzymes. The research generally probed the enzymes’ mechanism as a basis to understand and design active agents. He is particularly interested in tight-binding or inactivating enzyme inhibitors. His research group discovered inactivators of several key enzymes. One inactivator, eniluracil, is a potentiator of 5-fluorouracil, a cancer chemotherapy agent. Dr. Spector led the Phase II clinical trial of this combination therapy for metastatic breast cancer (ref. 105 in Publications: click to read Eniluracil MBC 2014).